Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet van Riel

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Rheumatology|May 8, 2003
MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritisGeorge Wells, Maarten Boers, Beverley Shea, et al.
The Journal of Rheumatology|November 5, 2002
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritisAlfons den Broeder, Leo van de Putte, Rolf Rau, et al.
Annals of the Rheumatic Diseases|January 3, 2012
A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registryLydia G Schipper, Marloes Vermeer, Hillechiena H Kuper, et al.
RMD Open|December 10, 2016
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic toolsPiet van Riel, Rieke Alten, Bernard Combe, et al.
The Journal of Rheumatology|May 8, 2003
MCID/Low Disease Activity State Workshop: summary, recommendations, and research agendaGeorge Wells, Jennifer Anderson, Maarten Boers, et al.
Annals of the Rheumatic Diseases|October 29, 2010
The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotypeKaren Dawidowicz, Yannick Allanore, Mickaël Guedj, et al.
Arthritis Research & Therapy|June 7, 2008
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritisRieke Alten, Hermann Gram, Leo A Joosten, et al.
RMD Open|June 24, 2026
Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Miguel A Gonzalez-Gay, Virginia Pascual-Ramos, et al.
Arthritis and Rheumatism|July 10, 2010
Identification of the oxidative stress-related gene MSRA as a rheumatoid arthritis susceptibility locus by genome-wide pathway analysisJose-Ezequiel Martín, Behrooz Z Alizadeh, Miguel A González-Gay, et al.
RMD Open|February 2, 2026
Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Virginia Pascual-Ramos, Miguel A Gonzalez-Gay, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Rheumatology|May 8, 2003
MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritisGeorge Wells, Maarten Boers, Beverley Shea, et al.
The Journal of Rheumatology|November 5, 2002
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritisAlfons den Broeder, Leo van de Putte, Rolf Rau, et al.
Annals of the Rheumatic Diseases|January 3, 2012
A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registryLydia G Schipper, Marloes Vermeer, Hillechiena H Kuper, et al.
RMD Open|December 10, 2016
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic toolsPiet van Riel, Rieke Alten, Bernard Combe, et al.
The Journal of Rheumatology|May 8, 2003
MCID/Low Disease Activity State Workshop: summary, recommendations, and research agendaGeorge Wells, Jennifer Anderson, Maarten Boers, et al.
Annals of the Rheumatic Diseases|October 29, 2010
The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotypeKaren Dawidowicz, Yannick Allanore, Mickaël Guedj, et al.
Arthritis Research & Therapy|June 7, 2008
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritisRieke Alten, Hermann Gram, Leo A Joosten, et al.
RMD Open|June 24, 2026
Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Miguel A Gonzalez-Gay, Virginia Pascual-Ramos, et al.
Arthritis and Rheumatism|July 10, 2010
Identification of the oxidative stress-related gene MSRA as a rheumatoid arthritis susceptibility locus by genome-wide pathway analysisJose-Ezequiel Martín, Behrooz Z Alizadeh, Miguel A González-Gay, et al.
RMD Open|February 2, 2026
Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritisGeorge A Karpouzas, Virginia Pascual-Ramos, Miguel A Gonzalez-Gay, et al.
Pageof 6